IO Biotech Inc. announced the publication of five-year clinical outcomes from the Phase 1/2 MM1636 trial in Nature Communications. The study evaluated the investigational peptide vaccine IO102-IO103, which targets cells expressing IDO1 and PD-L1, in combination with PD-1 blockade for the treatment of first-line metastatic melanoma. The five-year analysis reported a median progression-free survival of 25.5 months, a median duration of response of more than 53 months, and a median overall survival of 60 months. These results have already been published and supported the FDA Breakthrough Therapy Designation for IO102-IO103 in combination with pembrolizumab for unresectable/metastatic melanoma. The data also provided the foundation for the ongoing Phase 3 IOB-013/KN-D18 trial in first-line advanced melanoma.